News

Despite immune-related adverse events, concurrent ibrutinib and anti-CD19 CAR T-cell therapy may improve response rates in patients with chronic lymphocytic leukemia.

Analysis from a phase III trial confirmed the prognostic value of a 16-gene recurrence score in patients with high-risk renal cell carcinoma undergoing adjuvant sunitinib therapy.

Pazopanib 600 mg daily as adjuvant therapy did not prolong disease-free survival for patients with locally advanced renal cell carcinoma.

Concurrent treatment with CTL-119 cell therapy and ibrutinib (Imbruvica) led to complete marrow clearance of leukemic cells in 8 of 9 evaluable patients with heavily pretreated or genetically high-risk chronic lymphocytic leukemia, results of a pilot study showed.

The pharmacologic treatment for advanced renal cell carcinoma has evolved considerably since the FDA approved interleukin-2 as the first systemic therapy for the tumor type in 1992. Since then, the FDA has approved more than 20 drugs for RCC in the past 12 years.

A new gene therapy tested the efficacy of injecting a virus into the eye.

CAR T-cell therapy targeting B-cell maturation protein may be a new effective type of immunotherapy treatment for patients with multiple myeloma.

Early results from a Chinese study showed that 33 of 35 patients (94%) with relapsed or refractory multiple myeloma experienced clinical remission after treatment with chimeric antigen receptor T cells targeting B-cell maturation protein.

This review will focus on current therapies used in the first-line setting for advanced EGFR mutation positive non–small cell lung cancer (NSCLC) followed by emerging data that may lead to a transition in the choice for initial therapy in these patients.

The FDA has granted a priority review designation to sunitinib (Sutent) for use as an adjuvant therapy in patients with renal cell carcinoma who have received nephrectomy and are high risk for recurrence.

A new triple therapy approach using a checkpoint inhibitor and T-cell therapy is showing considerable promise in the treatment of Merkel cell carcinoma.

Based on the results of the phase 2 ZUMA-1 trial in patients with refractory non-Hodgkin lymphoma, Kite Pharma has submitted for, and received, a priority review for its chimeric antigen receptor (CAR)-T cell treatment, axicabtagene ciloleucel.

Higher doses of the kinase inhibitor brigatinib as second-line therapy for ALK-positive non–small-cell lung cancer may be an option for some patients.

More than one-third of patients with metastatic uveal melanoma had objective tumor regression when treated with adoptive transfer of autologous tumor-infiltrating lymphocytes.

This review will highlight the survival impact that rituximab therapy has had on major lymphoid malignancies, such as diffuse large B-cell lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, follicular lymphoma, and mantle cell lymphoma. We will also discuss alternative anti-CD20 monoclonal antibodies.

Researchers at Seattle Children's Research Institute announced the first-in-human clinical trial aimed to extend remission for children and young adults with leukemia treated with CAR T-cell immunotherapy.

Ruben Niesvizky, MD, discusses some of the exciting advances, the potential of chimeric antigen receptor T-cell therapy, and emerging combination regimens on the horizon in multiple myeloma.

It is increasingly important that nurses recognize cytokine release syndrome and other side effects that can be triggered by treatment with engineered CAR T-cell therapies.

The first cerebral edema death in the ZUMA-1 CAR T-cell therapy trial was disclosed today by Kite Pharma on a conference call with investors announcing the company’s first quarter financial results.

JUNO Therapeutics announced that it hopes to accelerate its process for developing CAR T cells from weeks to just 2 days.

Stephen M. Ansell, MD, PhD, discusses the potential of immunotherapy agents in lymphoma, ongoing clinical trials, and where this blends in with chimeric antigen receptor (CAR) T-cell therapy.

While there are many hurdles to overcome before the technology could be ready for commercial use, the experiment shows what could be possible for people living with diabetes.

Low disease burden prior to treatment with CD19-specific chimeric antigen receptor T-cell therapy appears to be a positive prognostic factor for long-term survival outcomes of patients with relapsed B-cell acute lymphoblastic leukemia.

A novel target, B-cell maturation antigen, has been identified for future therapeutic development as chimeric antigen receptor T-cell therapy for patients with multiple myeloma.

Administration of autologous HER2-specific CAR-modified virus specific T Cells was safe and had clinical benefit for some patients with progressive glioblastoma, a disease with limited effective therapeutic options.

Consolidation therapy with lenalidomide, bortezomib, and dexamethasone (RVD), when used in conjunction with stem cell transplantation, extended progression-free survival compared with RVD alone in patients with multiple myeloma.

Sophie Papa, MD, discusses the early-phase results and the logic behind studying CAR T-cell therapy in solid tumors, such as head and neck cancer.

The FDA has granted a breakthrough therapy designation to tisagenlecleucel-T (CTL019) for use as a treatment for adult patients with relapsed/refractory diffuse large B-cell lymphoma after the failure of at least 2 prior therapies.

Using state-of-the-art gene editing technology, researchers have discovered a promising target to treat atypical teratoid/rhabdoid tumor (AT/RT), a highly aggressive and therapy-resistant brain tumor.

Investigators at Virginia Commonwealth University Massey Cancer Center discuss the current treatment for children with high-risk neuroblastoma including high-dose chemotherapy, surgery, stem cell transplantation, radiation therapy, isotretinoin, and immunotherapy.